Why the study?
Does hydrochlorothiazide reverse or exacerbate nephrosclerosis and glomerular hypertension in L-NAME-treated spontaneously hypertensive rats?
Does hydrochlorothiazide reverse or exacerbate nephrosclerosis and glomerular hypertension in L-NAME-treated spontaneously hypertensive rats?
In a rat model of NO-blockade nephrosclerosis, hydrochlorothiazide exacerbated glomerular hypertension, proteinuria, and histopathological renal injury rather than reversing it.
Answers are grounded in this paper and cite their sources.
HCTZ may worsen glomerular hypertension in this NO-blockade model; hypothesis-generating for thiazide effects on human nephrosclerosis.
OBJECTIVE: To determine whether a diuretic can also reverse the clinical, systemic, renal and glomerular haemodynamic and pathological changes caused by nephrosclerosis. METHODS: Three groups of 20-week-old spontaneously hypertensive rats (SHR) were investigated: control male SHR; a similar group, administered 50 mg/l NG-nitro-L-arginine methyl ester (L-NAME) for 3 weeks; and SHR treated similarly with L-NAME but also with 80 mg/kg per day hydrochlorothiazide (HCTZ) by gavage for 3 weeks. RESULTS: The mean arterial pressure, cardiac output, effective renal plasma flow and glomerular filtration rate decreased as urinary volume increased in the SHR treated with HCTZ and L-NAME. A micropuncture study demonstrated increased glomerular capillary pressure (PG, 56 +/- 1 versus 68 +/- 3 mmHg) associated with increased efferent (2.1 +/- 0.2 versus 2.9 +/- 0.3 u) but no change in afferent arteriolar resistances compared with the SHR group treated with L-NAME only. In addition, HCTZ administration increased the juxtamedullary glomerular injury score (47 +/- 13 versus 114 +/- 29) associated with elevated urinary protein excretion (35 +/- 1 versus 53 +/- 13 mg/100 g body weight per 24 h) The afferent arteriolar injury score was not changed. The PG elevation was related not only to severe glomerulosclerosis but also to increased fibronectin and alpha-smooth muscle actin deposition. CONCLUSION: HCTZ administration exacerbated the changes in renal and micropuncture dynamics, proteinuria and histopathological nephrosclerosis produced by L-NAME in SHR.
No takes yet. Share an insight, caveat, or question.
Ono et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: